1. Home
  2. ATYR vs MG Comparison

ATYR vs MG Comparison

Compare ATYR & MG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • MG
  • Stock Information
  • Founded
  • ATYR 2005
  • MG 1978
  • Country
  • ATYR United States
  • MG United States
  • Employees
  • ATYR N/A
  • MG N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • MG Military/Government/Technical
  • Sector
  • ATYR Health Care
  • MG Consumer Discretionary
  • Exchange
  • ATYR Nasdaq
  • MG Nasdaq
  • Market Cap
  • ATYR 330.7M
  • MG 303.0M
  • IPO Year
  • ATYR 2015
  • MG 2009
  • Fundamental
  • Price
  • ATYR $3.73
  • MG $10.74
  • Analyst Decision
  • ATYR Strong Buy
  • MG Hold
  • Analyst Count
  • ATYR 6
  • MG 1
  • Target Price
  • ATYR $18.60
  • MG $11.00
  • AVG Volume (30 Days)
  • ATYR 1.9M
  • MG 142.4K
  • Earning Date
  • ATYR 03-13-2025
  • MG 03-05-2025
  • Dividend Yield
  • ATYR N/A
  • MG N/A
  • EPS Growth
  • ATYR N/A
  • MG N/A
  • EPS
  • ATYR N/A
  • MG 0.60
  • Revenue
  • ATYR $235,000.00
  • MG $729,640,000.00
  • Revenue This Year
  • ATYR $1,387.23
  • MG $5.79
  • Revenue Next Year
  • ATYR $873.22
  • MG $3.26
  • P/E Ratio
  • ATYR N/A
  • MG $16.77
  • Revenue Growth
  • ATYR N/A
  • MG 3.43
  • 52 Week Low
  • ATYR $1.42
  • MG $7.45
  • 52 Week High
  • ATYR $4.66
  • MG $12.44
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 54.37
  • MG 53.92
  • Support Level
  • ATYR $2.98
  • MG $9.64
  • Resistance Level
  • ATYR $4.32
  • MG $10.45
  • Average True Range (ATR)
  • ATYR 0.39
  • MG 0.44
  • MACD
  • ATYR 0.06
  • MG 0.00
  • Stochastic Oscillator
  • ATYR 72.14
  • MG 59.72

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About MG Mistras Group Inc

MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.

Share on Social Networks: